Amarantus Bioscience Holdings Inc (AMBS)

[Riskreturn168]

Blackhawks: AMBS's PR about the BD validation merely said it was positively confirmed. What most shareholders were looking for was the 96 and 98% specificity and sensitivity numbers, which the PR did not address. This was a failure in communication. Instead of it being a positive, the PR disappointed. That could have been handled better.